Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for its phase 3 AURORA trial of Descartes-08, an mRNA cell therapy candidate for myasthenia gravis (MG).

This approval means the FDA has deemed the trial design acceptable to support a future Biologics License Application for Descartes-08 in MG, contingent on trial outcomes.

“This SPA agreement marks an important milestone,” said Carsten Brunn, PhD, President and CEO of Cartesian: “It provides critical regulatory clarity and a clear path toward potential approval.”

The phase 3 AURORA trial will assess Descartes-08 versus placebo with a 1:1 randomisation. The treatment involves six once-weekly infusions without preconditioning chemotherapy in 100 participants with acetylcholine receptor autoantibody positive MG.

The primary endpoint is the proportion of Descartes-08 participants showing a three-point or more improvement in MG-ADL score at month 4 compared to placebo.

In December 2024, Cartesian announced positive results from the phase 2b trial, demonstrating deep and durable improvements in MG patients.

Dr Brunn noted: “Supported by compelling phase 2b results, we believe Descartes-08 has the potential to serve as a meaningful new therapy without the need for preconditioning chemotherapy.”

Myasthenia gravis is a chronic autoimmune disorder that causes muscle weakness and fatigue, often requiring chronic immunosuppressive medicines.

Descartes-08 is designed to target B-cell maturation antigen and is in clinical development for MG and systemic lupus erythematosus. Dr Brunn added: “We look forward to commencing the phase 3 AURORA trial in the first half of this year.”

GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE